Details of the Drug Combination

General Information of Drug Combination (ID: DC4E37A)

Drug Combination Name
AS-1949490 Endoxifen
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs AS-1949490   DMZ1OO0 Endoxifen   DMTX8IZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 1.84
Bliss Independence Score: 1.84
Loewe Additivity Score: 12.2
LHighest Single Agent (HSA) Score: 12.21

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of AS-1949490
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Investigative [2]
Indication(s) of Endoxifen
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [3]
Endoxifen Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [4]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 ClinicalTrials.gov (NCT02311933) Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer. U.S.National Institutes of Health.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).